Please ensure Javascript is enabled for purposes of website accessibility
FDA Allows Emergency Use of Remdesivir for Coronavirus
gvw_ap_news
By Associated Press
Published 5 years ago on
May 1, 2020

Share

WASHINGTON — U.S. regulators on Friday allowed emergency use of an experimental drug that appears to help some coronavirus patients recover faster.

It is the first drug shown to help fight COVID-19, which has killed more than 230,000 people worldwide.

The FDA said in a statement that Gilead Science’s intravenous drug would be specifically indicated for hospitalized patients with “severe disease,” such as those experiencing breathing problems requiring supplemental oxygen or ventilators.

The study of 1,063 patients is the largest and most strict test of the drug and included a comparison group that received just usual care so remdesivir’s effects could be rigorously evaluated.

President Donald Trump announced the news at the White House alongside Gilead CEO Daniel O’Day and Food and Drug Administration Commissioner Stephen Hahn.

The FDA acted after preliminary results from a government-sponsored study showed that the drug, remdesivir, shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients.

The study of 1,063 patients is the largest and most strict test of the drug and included a comparison group that received just usual care so remdesivir’s effects could be rigorously evaluated.

Those given the drug were able to leave the hospital in 11 days on average vs. 15 days for the comparison group.

The FDA said that performance warranted Friday’s decision, though regulators acknowledged “there is limited information known about the safety and effectiveness of using remdesivir.”

The drug’s side effects include potential inflammation of the liver and problems related to its infusion, which could lead to nausea, vomiting, sweating and low blood pressure. Fact sheets about dosing and potential safety issues will be provided to physicians and patients, the FDA said.

The National Institutes of Health’s Dr. Anthony Fauci said Wednesday the drug would become a new standard of care for severely ill COVID-19 patients. The drug, which blocks an enzyme the virus uses to copy its genetic material, has not been tested on people with milder illness.

The FDA authorized the drug under its emergency powers to quickly speed experimental drugs, tests and other medical products to patients during public health crises.

Remdesivir Will Still Need Formal Approval

In normal times the FDA requires “substantial evidence” of a drug’s safety and effectiveness, usually through one or more large, rigorously controlled patient studies. But during public health emergencies the agency can waive those standards, simply requiring that an experimental drug’s potential benefits outweigh its risks.

Gilead has said it would donate its currently available stock of the drug and is ramping up production to make more. It said the U.S. government would coordinate distribution of remdesivir to places most in need of it.

No drugs are approved now for treating the coronavirus, and remdesivir will still need formal approval.

The FDA can convert the drug’s status to full approval if Gilead or other researchers provide additional data of remdesivir’s safety and effectiveness.

“This is a very, very early stage so you wouldn’t expect to have any sort of full approval at this point,” said Cathy Burgess, an attorney specializing in FDA issues. “But obviously they want to get this out to patients as quickly as possible.”

The FDA previously allowed narrow use of a malaria drug, hydroxychloroquine, for hospitalized patients who were unable to take part in ongoing studies of the medication. Trump repeatedly promoted it as a possible COVID-19 treatment, but no large high-quality studies have shown the drug to work for that and it has significant safety concerns.

The FDA warned doctors late last month against prescribing the drug outside of hospital or research settings, due to risks of sometimes fatal heart side effects.

Two small studies published Friday add to concerns about the malaria drug. Critically ill COVID-19 patients given hydroxychloroquine were prone to heart rhythm problems, and for many risks mounted when it was combined with an antibiotic, the studies found.

RELATED TOPICS:

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Newsom Wants to Bypass Trump Tariffs With Direct CA Trade Deals

DON'T MISS

Markets Plunge With S&P 500 Down 6% and Dow Down 2,200 After China Retaliates

DON'T MISS

Fresno Police Searching for Missing 12-Year-Old Girl

DON'T MISS

Madera Community College Unveils New Multicultural and Veterans Center

DON'T MISS

Fusion Energy Race Is On. Two Local Lawmakers Want California to Lead the Way

DON'T MISS

Saturday’s Spring Fest to Showcase Free, Low-Cost Activities for Fresno Kids

DON'T MISS

LA County Reaches $4 Billion Agreement to Settle Sexual Abuse Claims at Juvenile Facilities

DON'T MISS

Fresno Man Sentenced to 14 Years in Prison for Deadly Marijuana DUI Crash

DON'T MISS

Judge Says US Must Return Maryland Man Who Was Mistakenly Deported to El Salvador Prison

DON'T MISS

These Fresno First-Graders Are Topping Their Peers in Reading

UP NEXT

The NBA’s Playoff Chase Enters Its Final Days. Here’s a Look at What’s Happening

UP NEXT

USC’s JuJu Watkins Named AP Player of the Year After Historic Sophomore Season

UP NEXT

Dodgers’ Freddie Freeman Lands on Injured List Following Fall in His Shower at Home

UP NEXT

How Trump’s Latest Tariffs Could Affect Your Wallet

UP NEXT

Curry Scores 37 Points and Warriors Beat Lakers in a Potential First-Round Playoff Preview

UP NEXT

Wired Wednesday: CEMEX’s New Mining Plan for the San Joaquin River

UP NEXT

Measles Spreads to Central Texas; 5 States Have Active Outbreaks

UP NEXT

Startup Offers Controversial Microplastic Blood Cleansing Treatment

UP NEXT

Pence Will Receive the Profile in Courage Award From the JFK Library for His Actions on Jan. 6

UP NEXT

Flores Homers, Matos and Wade Also Go Deep to Help Giants Cap Sweep of Astros

Madera Community College Unveils New Multicultural and Veterans Center

9 hours ago

Fusion Energy Race Is On. Two Local Lawmakers Want California to Lead the Way

9 hours ago

Saturday’s Spring Fest to Showcase Free, Low-Cost Activities for Fresno Kids

10 hours ago

LA County Reaches $4 Billion Agreement to Settle Sexual Abuse Claims at Juvenile Facilities

10 hours ago

Fresno Man Sentenced to 14 Years in Prison for Deadly Marijuana DUI Crash

10 hours ago

Judge Says US Must Return Maryland Man Who Was Mistakenly Deported to El Salvador Prison

10 hours ago

These Fresno First-Graders Are Topping Their Peers in Reading

11 hours ago

Fresno Burial Ceremony to Honor Five Abandoned Babies Set for Saturday

11 hours ago

Visalia Man Arrested for Soliciting Sex From Minor in Kingsburg

12 hours ago

Camalah Saleh Cruises to Win in Stormy Fresno State Student Elections

13 hours ago

Newsom Wants to Bypass Trump Tariffs With Direct CA Trade Deals

Gov. Gavin Newsom on Friday asked exporting countries worldwide to spare California their retaliatory tariffs, saying he plans to pursue dir...

8 hours ago

8 hours ago

Newsom Wants to Bypass Trump Tariffs With Direct CA Trade Deals

Specialist Anthony Matesic works on the floor of the New York Stock Exchange, Friday, April 4, 2025. (AP/Richard Drew)
8 hours ago

Markets Plunge With S&P 500 Down 6% and Dow Down 2,200 After China Retaliates

Fresno police are searching for Unique Hernandez, 12, last seen on Friday, April 4, 2025, near Inyo Street and Maple Avenue, wearing all black clothing and carrying a black backpack. (Fresno PD)
8 hours ago

Fresno Police Searching for Missing 12-Year-Old Girl

9 hours ago

Madera Community College Unveils New Multicultural and Veterans Center

9 hours ago

Fusion Energy Race Is On. Two Local Lawmakers Want California to Lead the Way

10 hours ago

Saturday’s Spring Fest to Showcase Free, Low-Cost Activities for Fresno Kids

10 hours ago

LA County Reaches $4 Billion Agreement to Settle Sexual Abuse Claims at Juvenile Facilities

Antonio de Jesus Orozco Montes Deoca, 30, was sentenced on Friday, March 4, 2025, to 14 years and 8 months in prison for a deadly marijuana DUI crash in 2022 that killed one woman and injured four others. (GV Wire Composite)
10 hours ago

Fresno Man Sentenced to 14 Years in Prison for Deadly Marijuana DUI Crash

Help continue the work that gets you the news that matters most.

Search

Send this to a friend